Most participants, especially within the adult patient subgroup, were relatively well informed about CFTR modulators, including their genetic aspects: “I have been very excited to see the new developments that are happening, particularly with treating CF on a more cellular level, rather than just treating the major symptoms!” (P6). This evidence concerns the gene CFTR and cystic fibrosis.